Natera, Inc. (NTRA) Posts Earnings Results, Hits Estimates
Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Tuesday. The medical research company reported ($0.52) EPS for the quarter, hitting analysts’ consensus estimates of ($0.52), Briefing.com reports. Natera had a negative net margin of 60.89% and a negative return on equity of 101.63%. The firm had revenue of $53.60 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same period in the previous year, the company earned ($0.46) EPS. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year.
Natera (NASDAQ NTRA) traded up 26.84% during trading on Wednesday, hitting $10.35. 1,117,886 shares of the company were exchanged. The company’s market capitalization is $547.33 million. Natera has a 12 month low of $7.35 and a 12 month high of $12.95. The stock’s 50-day moving average is $10.15 and its 200-day moving average is $9.55.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. acquired a new position in Natera during the fourth quarter valued at approximately $130,000. American International Group Inc. raised its position in Natera by 7.1% in the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after buying an additional 194 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Natera during the second quarter valued at approximately $151,000. Finally, Goldman Sachs Group Inc. raised its position in Natera by 45.3% in the first quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock valued at $154,000 after buying an additional 5,417 shares during the last quarter. 59.74% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts recently commented on the stock. BidaskClub cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Morgan Stanley dropped their price target on shares of Natera from $18.00 to $13.00 and set an “overweight” rating for the company in a research note on Monday. ValuEngine cut shares of Natera from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Canaccord Genuity lifted their price target on shares of Natera from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Finally, Zacks Investment Research cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Four investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.80.
TRADEMARK VIOLATION WARNING: “Natera, Inc. (NTRA) Posts Earnings Results, Hits Estimates” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/natera-inc-ntra-posts-earnings-results-hits-estimates.html.
Natera Company Profile
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.